| abstract |
The present invention relates generally to the field of therapeutic compounds. More particularly, the present invention relates to certain 4 - [[(7-aminopyrazolo [1,5-a] pyrimidin-5-yl) amino] methyl] piperidin-3-ol compounds (referred to herein as "APPAMP compounds"). ") which, inter alia, inhibit (e.g. selectively) CDK (e.g., CDK1, CDK2, CDK4, CDK5, CDK6, CDK7, CDK8, CDK9, CDK10, CDK11, CDK12, CDK13, etc.). The present invention also relates to pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions, both in vitro and in vivo, in the inhibition of CDK; and in the treatment of disorders comprising: disorders related to CDK; disorders resulting from inappropriate activity of a cyclin-dependent kinase (CDK); disorders associated with CDK mutation; disorders associated with overexpression of CDK; disorders associated with activation upstream of the CDK pathway; disorders that are enhanced by inhibition of CDK; proliferative disorders; the cancer ; viral infections (including HIV); neurodegenerative disorders (including Alzheimer's disease and Parkinson's disease); ischemia; kidney disease; cardiovascular disorders (including atherosclerosis); and autoimmune disorders (including rheumatoid arthritis). Optionally, the treatment also includes treatment (e.g., simultaneous or sequential treatment) with an additional active ingredient, for example, an aromatase inhibitor, an anti-estrogen, a Her2 blocking agent, a cytotoxic chemotherapeutic agent. etc. |